Clinical trials: Neoplasm Recurrence, Local
Recurrent Head and Neck Cancer, Local Cryotherapy Treatment
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study
In France, squamous cell carcinomas of the head and neck (SCCHN) are the 5th most common cancer. 60% of patients present with locally advanced tumors (stage III/IV), characterized by a poor prognosis (5-year survival not…
- Trial name
- CRYORL (NCT05738187)
- Testing
- local cryotherapy treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Neuroblastoma
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00072358
- Testing
- anti-GD2 murine IgG3 monoclonal antibody 3F8
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Glioblastoma, CD147 Positive
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
- Trial name
- NCT04045847
- Testing
- CD147-CART
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population.
- Trial name
- NCT02974426
- Testing
- PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Chest Hospital
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Nasopharyngeal Carcinoma
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03210389
- Testing
- Lobaplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Lumpectomy
Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer
The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast.
- Trial name
- SHARE (NCT01247233)
- Testing
- Whole Breast Irradiation + Boost or Hypofractionated irradiation, Accelerated partial breast irradiation
- Where
- 34 sites in France
- Volunteers
- 1,006 people
- Sponsor
- UNICANCER
Colorectal Cancer, Colorectal Neoplasms
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I
- Trial name
- T1CR (NCT06314971)
- Testing
- Tw1CE
- Where
- 3 sites in United States, Japan and 1 more
- Volunteers
- 138 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer Recurrent
Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI
Inclusion criteria: Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR Patients referred to our institution for biopsy-proven…
- Trial name
- HISTO-RAD (NCT01857037)
- Testing
- Histoscanning™ and multiparametric MRI
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations.
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03410043
- Testing
- Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer
This randomized phase III trial is studying surgery and axillary lymph node dissection to evaluate if systematic Axillary Lymph Node Excision can be avoided in locoregional treatment for operable breast cancer smaller than 10 mm…
- Trial name
- AXIL95 (NCT00210236)
- Testing
- Conventional surgery WITHOUT Axillary Lymph Node Excision, Conventional surgery WITH Axillary Lymph Node Excision
- Where
- 14 sites in France
- Volunteers
- 625 people
- Sponsor
- Institut Bergonié
Esophageal Squamous Cell Carcinoma (ESCC)
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
The combination of programmed death receptor 1 (PD-1) inhibitors with chemotherapy has been recognized for the treatment of advanced and metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- ESO-Nanjing12 (NCT07016737)
- Testing
- Sintilimab Combined With Docetaxel Monotherapy
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ye jinjun
Recurrent Nasopharyngeal Carcinoma
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT04376866
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse.
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor
- Trial name
- NCT01841736
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 423 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Local Neoplasm Recurrence, Toxicity
Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT)
Title: HIOB - Hypofractionated Whole-Breast Irradiation preceded by Intraoperative Radiotherapy with Electrons as anticipated Boost ISIORT- 01 HIOB is defined as hypofractionated WBRT (40,5 Gy in 2,7 Gy per fraction) preceded by…
- Trial name
- HIOB (NCT01343459)
- Testing
- HIOB
- Where
- Austria
- Volunteers
- 1,464 people
- Sponsor
- Paracelsus Medical University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00066612
- Testing
- irinotecan hydrochloride
- Volunteers
- 45 people
- Sponsor
- SWOG Cancer Research Network
Liver Cancer, Cancer, Treatment-Related
Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?
Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery.
- Trial name
- LIVERaTION (NCT05492136)
- Testing
- Additional margin coagulation
- Where
- Spain
- Volunteers
- 720 people
- Sponsor
- Hospital del Mar
Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
RATIONALE: Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00450307
- Testing
- monoclonal antibody 3F8, sargramostim
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High Grade Glioma
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week.
- Trial name
- NCT04254419
- Testing
- NK cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Nationwide Children's Hospital